Modulation of anxiety through blockade of anandamide hydrolysis

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 76-81

  Kathuria, Satish ^a   Gaetani, Silvana ^a   Fegley, Darren ^a   Valiño, Fernando ^a   Duranti, Andrea ^b   Tontini, Andrea ^b   Mor, Marco ^c   Tarzia, Giorgio ^b   La Rana, Giovanna ^d   Calignano, Antonio ^d   Giustino, Arcangela ^e   Tattoli, Maria ^e   Palmery, Maura ^f   Cuomo, Vincenzo ^f   Piomelli, Daniele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; BENZODIAZEPINE DERIVATIVE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENZYME INHIBITOR; FATTY ACID AMIDASE; UNCLASSIFIED DRUG; URB 532;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; IN VIVO STUDY; MAZE TEST; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; RAT; VOCALIZATION;

AMIDOHYDROLASES; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; CANNABINOIDS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; NEURONS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; VOCALIZATION, ANIMAL;

ANIMALIA; CANNABIS;

EID: 0037234363     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm803     Document Type: Article

References (45)

1. Devane, W.A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
2. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691 (1994).
3. Giuffrida, A. et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci. 2, 358-363 (1999).
4. Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097 (1997).
5. Cravatt, B.F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87 (1996).
6. Patricelli, M.P., Lovato, M.A. & Cravatt, B.F. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry 38, 9804-9812 (1999).
7. Rodríguez de Fonseca, F. et al. An anorexic lipid mediator regulated by feeding. Nature 414, 209-212 (2001).
8. Calignano, A., La Rana, G., Giuffrida, A. & Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281 (1998).
9. Cravatt, B.F. et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98, 9371-9376(2001).
10. Hall, W. & Solowij, N. Adverse effects of cannabis. Lancet 352, 1611-1616 (1998).
11. Chaperon, F. & Thiébot, M.H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13, 243-281 (1999).
12. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. 269, 22937-22940 (1994).
13. Beltramo, M., di Tomaso, E. & Piomelli, D. Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. FEBS Lett. 403, 263-267 (1997).
14. De Petrocellis, L. et al. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem. Biophys. Res. Commun. 231, 82-88 (1997).
15. Deutsch, D.G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. 231, 217-221 (1997).
16. Boger, D.L. et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA 97, 5044-5049 (2000).
17. Dinh, T.P. et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99, 10819-10824 (2002).
18. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90 (1995).
19. Sugiura, T. et al. 2-Arachidonoylglycerol; a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97 (1995).
20. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778 (1997).
21. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87, 1932-1936 (1990).
22. Glass, M., Dragunow, M. & Faull, R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299-318 (1997).
23. Katona, I. et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 21, 9506-9518, (2001).
24. Robson, P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry 178, 107-115 (2001).
25. Rodríguez de Fonseca, F., Carrera, M.R.A., Navarro, M., Koob, G.F. & Weiss, F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276, 2050-2054 (1997).
26. Arévalo, C., de Miguel, R. & Hernández-Tristán, R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 70, 123-131 (2001).
27. Martin, M., Ledent, C., Parmentier, M., Maldonado, R. & Valverde, O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159, 379-387 (2002).
28. Bickerdike, M.J., Marsden, C.A., Dourish, C.T. & Fletcher, A. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur. J. Pharmacol. 271, 403-411 (1994).
29. Shepherd, J.K., Grewal, S.S., Fletcher, A., Bill, D.J. & Dourish, C.T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 116, 56-64 (1994).
30. Insel, T.R., Hill, J.L. & Mayor, R.B. Rat pup ultrasonic isolation calls: possible mediation by the benzodiazepine receptor complex. Pharmacol. Biochem. Behav. 24, 1263-1267 (1986).
31. A and 5-HT anxiolytics. Psychopharmacology 121, 38-56 (1995).
32. Winslow, J.T. & Insel, T.R. Infant rat separation is a sensitive test for novel anxiolytics. Prog. Neuropsychopharmacol. Biol. Psychiatry 15, 745-757 (1991).
33. Cahill, L. & McGaugh, I.L. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci. 21, 294-299 (1998).
34. McDonald, A.J. & Mascagni, F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 107, 641-652 (2001).
35. Fink, H., Rex, A., Voits, M. & Voigt, J.P. Major biological actions of CCK: a critical evaluation of research findings. Exp. Brain Res. 123, 77-83 (1998).
36. Beinfeld, M.C. & Connolly, K. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci. Lett. 301, 69-71 (2001).
37. Iversen, L. & Chapman, V. Cannabinoids: a real prospect for pain relief? Curr. Opin. Pharmacol. 2, 50-55 (2002).
38. Stella, N. & Piomelli, D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425, 189-196 (2001).
39. Giuffrida, A., Rodríguez de Fonseca, F. & Piomelli, D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 280, 87-93 (2000).
40. Piomelli, D. et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA 96, 5802-5807 (1999).
41. Tseng, A.H. & Craft, R.M. Sex differences in antinociceptive and motoric effects of cannabinoids. Eur. J. Pharmacol. 430, 41-47 (2001).
42. Ali, M.M., Bawari, M., Misra, U.K. & Babu, G.N. Locomotor and learning deficits in adult rats exposed to monosodium-L-glutamate during early life. Neurosci. Lett. 284, 57-60 (2000).
43. Wedzony, K. et al. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23, 547-559 (2000).
44. Cuomo, V., Cagiano, R., Renna, G., De Salvia, M.A. & Racagni, G. Ultrasonic vocalization in rat pups: effects of early postnatal exposure to SCH 23390 (a DA1-receptor antagonist) and sulpiride (a DA2-receptor antagonist). Neuropharmacology 26, 701-705 (1987).
45. Haller, J., Bakus, N., Szirmay, M., Ledent, C. & Freund, T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. (in the press).